ID   SupT1-CIITA
AC   CVCL_C6JB
SY   SupT1-CIITA B5; SupT1.CIITA
DR   PRIDE; PXD013015
DR   Wikidata; Q116050582
RX   PubMed=21041720;
RX   PubMed=31020640;
CC   Population: Caucasian.
CC   Virology: Has an enhanced susceptibility to infection by HIV-1 (PubMed=21041720).
CC   Virology: Susceptible to infection by herpesvirus 6B (HHV-6B) strain Z29 (PubMed=31020640).
CC   HLA typing: DRB1*03:01,13:01; DRB3*01:01,02:02 (PubMed=31020640).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: HGNC; 7067; CIITA.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Omics: HLA class II peptidome analysis by proteomics.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7210; Childhood T lymphoblastic lymphoma
DI   ORDO; Orphanet_171918; T-cell non-Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1714 ! SUP-T1
SX   Male
AG   8Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 05-10-23; Version: 4
//
RX   PubMed=21041720; DOI=10.4049/jimmunol.1000830;
RA   Porter K.A., Kelley L.N., Nekorchuk M.D., Jones J.H., Hahn A.B.,
RA   de Noronha C.M.C., Harton J.A., Duus K.M.;
RT   "CIITA enhances HIV-1 attachment to CD4+ T cells leading to enhanced
RT   infection and cell depletion.";
RL   J. Immunol. 185:6480-6488(2010).
//
RX   PubMed=31020640; DOI=10.1002/eji.201948126;
RA   Becerra-Artiles A., Cruz J., Leszyk J.D., Sidney J., Sette A.,
RA   Shaffer S.A., Stern L.J.;
RT   "Naturally processed HLA-DR3-restricted HHV-6B peptides are recognized
RT   broadly with polyfunctional and cytotoxic CD4 T-cell responses.";
RL   Eur. J. Immunol. 49:1167-1185(2019).
//